Key result
DOACs show lower bleeding signals than VKAs in hemodialysis AF patients alongside comparable stroke prevention.
Why the study?
While the transition from VKAs to DOACs is established in the general population and moderate CKD, anticoagulation management remains uncertain in haemodialysis patients with AF due to limited evidence.
Do DOACs or LAAO improve stroke prevention and reduce bleeding risk compared to VKAs in hemodialysis patients with atrial fibrillation?
Population
Haemodialysis patients with AF
Comparison
DOACs vs VKAs vs LAAO
Design
Review
Authors
Loading...
Clinicians may cautiously prefer DOACs over VKAs in AF on HD; leaves open confirmation by dedicated RCTs.
Do DOACs or LAAO improve stroke prevention and reduce bleeding risk compared to VKAs in hemodialysis patients with atrial fibrillation?
In hemodialysis patients with atrial fibrillation, current evidence suggests a cautious preference for DOACs over VKAs due to lower bleeding risk and comparable stroke prevention.
Triantafyllidou et al. (2026) conducted a review in Hemodialysis patients with Atrial Fibrillation. Direct Oral Anticoagulants (DOACs) vs. Vitamin K Antagonists (VKAs) was evaluated. Direct oral anticoagulants are cautiously preferred over vitamin K antagonists in hemodialysis patients with atrial fibrillation due to signals of lower bleeding and comparable stroke prevention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: